GLP-1s and Alcohol: Why People on Weight Loss Medication Are Drinking Less

The short answer

Why would a weight loss medication touch alcohol at all?

The popular explanation for how GLP-1 class medications work is that they slow gastric emptying and make you feel full sooner. That is true, and it is incomplete.

GLP-1 receptors are also expressed in regions of the brain involved in reward processing and motivation, including the ventral tegmental area and nucleus accumbens. Animal work going back more than a decade showed GLP-1 receptor agonists reducing alcohol intake in rodents, which is suggestive but not sufficient. Rodent data is a reason to run a human trial. It is not a reason to tell a patient anything.

The human trials arrived, and they are worth reading carefully rather than reading about.

What did the JAMA Psychiatry trial actually find?

Hendershot and colleagues published a phase 2, double-blind, randomized trial in JAMA Psychiatry in February 2025. Forty-eight adults with alcohol use disorder were randomized to weekly semaglutide or placebo, titrated to 1.0 mg, over roughly 9 weeks.

The design included a laboratory self-administration component, which matters. Instead of relying only on what people reported about their own drinking, participants were given access to alcohol in a controlled setting and researchers measured how much they actually consumed. In that lab setting, the medication group drank less, with medium-to-large effect sizes on grams of alcohol consumed and peak breath alcohol concentration. Over the weeks, the medication group also reported lower craving and fewer drinks on the days they did drink. A secondary finding: smokers in the group smoked less.

Forty-eight people is a small trial. Nine weeks is a short one. This is a signal, not a settled conclusion.

What did the 2026 Lancet trial add?

The larger follow-up was published in The Lancet in 2026 and summarized by the National Institutes of Health. It enrolled 108 treatment-seeking adults who had both alcohol use disorder and obesity, randomized to once-weekly semaglutide or placebo for 26 weeks. Everyone in the trial also received cognitive behavioral therapy.

That last detail is the one most coverage skips. Both groups got structured behavioral treatment. Both groups improved. The placebo group cut heavy drinking days by 27.4%. The medication group cut them by 41.1%. The medication added about 13.7 percentage points on top of therapy that was already working.

Reductions in body weight and blood pressure were also more pronounced in the medication group. Gastrointestinal side effects occurred and were described as transient and mild.

Read that structure again, because it is the whole lesson: the drug was an addition to a program, not a replacement for one.

Does this mean GLP-1 medication treats alcohol use disorder?

No, and this is where the internet gets ahead of the evidence.

No GLP-1 class medication is FDA-approved for alcohol use disorder, alcohol craving, or any addiction indication. Using one for that purpose is investigational and off-label. Two randomized trials totaling 156 participants, run for 9 and 26 weeks, are early-stage evidence. The investigators themselves said questions remain and that longer, larger studies are needed.

There are established, FDA-approved medications for alcohol use disorder, and there is real behavioral treatment for it. Anyone concerned about their drinking should be talking with a licensed clinician who treats it, not reading a wellness blog. If drinking is a problem, that conversation deserves its own appointment, not a footnote in a weight loss visit. SAMHSA's national helpline is 1-800-662-4357.

What this research legitimately supports is narrower and still useful: these medications appear to influence craving and reward, and that mechanism shows up in more places than the dinner plate.

What does this actually mean for someone on medically supervised weight loss?

Three practical things.

First, expect appetite changes that are not about food. Patients regularly describe losing interest in things they used to reach for automatically, and alcohol is the one that comes up most. If that happens, it is consistent with what the mechanism predicts. It is not a sign something is wrong.

Second, the reverse also matters. Alcohol is not neutral on any of the numbers a weight loss program tracks. It is dense in calories with no protein, it fragments sleep architecture even at modest intake, it raises liver enzymes, it contributes to visceral fat accumulation, and it worsens vasomotor symptoms for a lot of women in perimenopause. If a medication makes drinking less appealing, that is a window. The program should use it rather than ignore it.

Third, nothing here changes the fundamentals. A medication that reduces appetite for food and drink still does not build muscle, does not fix sleep, and does not tell you what your labs are doing. That is why our medically supervised weight loss program pairs provider-prescribed medication with a resistance training plan, a protein target, and repeat lab work. A prescription with no program attached is how people lose lean mass and regain weight. The Lancet trial makes the same point from a different direction: therapy plus medication beat therapy alone, but therapy alone still worked.

What should be measured while someone is on this medication?

If alcohol intake is changing, some numbers are worth watching as part of routine follow-up rather than assuming everything is fine. Liver enzymes and GGT respond to alcohol intake. So do triglycerides, fasting glucose and insulin, blood pressure, and sleep quality. Body composition matters more than scale weight, because two people down 20 pounds can have very different lean mass outcomes.

This is the part a telehealth refill loop is not built to do. Our lab and genomic testing exists so the numbers get looked at by someone who knows the person attached to them. Our collaborating NP or MD orders the testing and writes every prescription. I build the program and coach the training. Both parts have to be there.

Local questions we hear in Dartmouth and across the SouthCoast

The honest summary

Two randomized trials found that a GLP-1 class medication reduced drinking more than placebo, one of them on top of behavioral therapy that was already working. The effect is real enough to take seriously and preliminary enough that nobody should be making promises about it. No medication in this class is approved for alcohol use, and anyone whose drinking worries them needs a clinician who treats that specifically.

The broader takeaway is the one worth keeping: these medications work on craving and reward, not only on fullness. That is a powerful mechanism and a reason for supervision, lab follow-up, and a training plan, rather than a prescription arriving in the mail every month with nobody checking anything.

Book a consultation

If you are considering medically supervised weight loss, or you are already on medication and nobody has looked at your labs or your training since you started, book a free discovery call. It is a conversation. We will look at what you have, tell you what we would want to measure, and you decide from there. In-person care in Dartmouth, MA, serving New Bedford, Westport, Fairhaven, Fall River, and the SouthCoast.

You can read more of our education articles here.

Educational disclaimer: This article is general health education and is not medical advice, diagnosis, or treatment, and it does not create a clinician-patient relationship. Justin Coelho is a registered nurse and does not diagnose, prescribe, or independently order testing; all prescriptions and lab orders at Vitality Dartmouth are written by a collaborating NP or MD. GLP-1 class medications are not FDA-approved for alcohol use disorder or alcohol craving; use for that purpose is investigational and off-label. Individual results vary. Talk with your own licensed healthcare provider before starting, stopping, or changing any medication, supplement, or exercise program. If you are concerned about your alcohol use, contact a licensed clinician or the SAMHSA National Helpline at 1-800-662-4357.